DarioHealth Corp [DRIO] stock prices are up 0.66% to $1.53 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The DRIO shares have gain 4.79% over the last week, with a monthly amount drifted -30.77%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results. In a post published today on Yahoo Finance, Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased.
From an analyst’s perspective:
DarioHealth Corp [NASDAQ: DRIO] stock has seen the most recent analyst activity on May 13, 2022, when Alliance Global Partners upgraded its rating to a Buy but kept the price target unchanged to $8.75 for it. Previously, Cowen started tracking the stock with Outperform rating on April 22, 2021, and set its price target to $31. On March 23, 2021, Stifel initiated with a Buy rating and assigned a price target of $30 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $35 on February 25, 2021. Alliance Global Partners downgraded its rating to a Neutral and raised its price target to $22.25 on February 01, 2021. Aegis Capital started tracking with a Buy rating for this stock on August 17, 2020, and assigned it a price target of $25. In a note dated August 29, 2017, Aegis Capital initiated an Buy rating and provided a target price of $3.50 on this stock.
The stock price of DarioHealth Corp [DRIO] has been fluctuating between $0.68 and $4.58 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. DarioHealth Corp [NASDAQ: DRIO] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 602.61% based on the average DRIO price forecast.
Analyzing the DRIO fundamentals
The DarioHealth Corp [NASDAQ:DRIO] reported sales of 23.55M for trailing twelve months, representing a drop of -46.74%. Gross Profit Margin for this corporation currently stands at 0.36% with Operating Profit Margin at -2.17%, Pretax Profit Margin comes in at -1.07%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.0 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4133 points at the first support level, and at 1.2967 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6533, and for the 2nd resistance point, it is at 1.7767.
DarioHealth Corp [DRIO] reported earnings per share of -$0.49 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.46/share, meaning a difference of -$0.03 and a surprise factor of -6.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.58 per share as compared to estimates of -$0.52 per share, a difference of -$0.06 representing a surprise of -11.50%.
Ratios To Look Out For
It’s worth pointing out that DarioHealth Corp [NASDAQ:DRIO]’s Current Ratio is 6.93. On the other hand, the Quick Ratio is 6.26, and the Cash Ratio is 5.41. Considering the valuation of this stock, the price to sales ratio is 1.77, the price to book ratio is 0.61.
